Global Short Bowel Syndrome Drugs Market – Industry Trends and Forecast to 2029

Global Short Bowel Syndrome Drugs Market, By Drug Class (Glucagon-like Peptide, Anti-Diarrheal, Histamine Blockers, Proton Pump Inhibitors, Growth Hormone, Others), Route of Administration (OralParenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Short Bowel Syndrome Drugs Market Analysis and Size

Short bowel syndrome is related with small intestine surgeries. It is characteristically acquired over the individual’s lifespan and genetically occurs only in few cases.  Currently, there is no cure for short bowel syndrome and the treatment is targeted toward its symptoms. In some cases, short bowel syndrome can be life-threatening, but the disease can be managed through effective medication. In addition to this, government bodies are directly taking part in boosting the confidence of local manufacturers through various initiatives.

Data Bridge Market Research analyses a growth rate in the global short bowel syndrome drugs market in the forecast period 2022-2029. The expected CAGR of global short bowel syndrome drugs market is tend to be around 15% in the mentioned forecast period. The market was valued at USD 1.44 billion in 2021, and it would grow upto USD 4.40 billion by 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Short Bowel Syndrome Drugs Market Scope and Segmentation

Market Definition

Short bowel syndrome drugs is a type of rare gastrointestinal disease wherein a patient either lose a large amount of intestine or are born with inadequate amount of intestine as well as dysfunctional intestine that finally results in the malnutrition because it cannot effectively absorb the nutrients from the food.  

Global Short Bowel Syndrome Drugs Market Dynamics

Drivers

• Increased Demand of Intravenous Supplementation of Fluids

There is a rising demand for intravenous supplementation of fluids for maintaining the normal hydration and urinary flow for patients who are suffering from this syndrome. Several key manufacturers in the short bowel syndrome market are making efforts to meet this demand, since these patients suffer from complications such as hyponatremia, dehydration, and chronic renal failure. Hypomagnesemia is caused by malabsorption of magnesium because of the loss of the distal ileum, several manufacturers are producing magnesium supplements to help the patients achieve adequate hydration.

• Prevalence of Short Bowel Syndrome

Incidence of short bowel syndrome has increased across the globe in the past few years. The increasing patients number on total parenteral nutrition has led to the increase in the market growth. The occurrence of short bowel syndrome is projected to be about four people per million, and the occurrence is about three people per million. Although the exact prevalence of the disease is not clear, it is expected based on the number of people on parenteral nutrition.

Opportunities

• High Cost of Parenteral Nutrition

The huge cost of parenteral nutrition increases the demand for short bowel syndrome drugs, that have clearly shown the ability to reduce patients' dependence on parenteral nutrition during clinical trials. For instance, apraglutide has the advantage to enable patients to reduce the burden from parenteral support by growing intestinal absorption of fluids, calories, and nutrients. Apraglutide has completed phase 2 trial and is currently being assessed in a pivotal phase 3 clinical trial.

• Increasing Demand for Retail Pharmacies

The rise in the number of short bowel syndrome drugs delivered through retail pharmacies and the increase in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients opt for retail pharmacies for buying drugs, as these are easily available.

 Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel who are unable to treat the patients with these agents could curb the growth of the global short bowel syndrome drugs market over a forecast period.

• High Cost

The cost of treatment of these type of syndromes  is significantly high, that makes the treatment unaffordable, especially for low-income groups. For instance, in May 2019, the U.S. FDA approved extending the indication of Gattex (teduglutide) for injection to paediatric patients with an age group of 1 year and older with short bowel syndrome (SBS). Gattex (teduglutide) is an injectable drug that is used to treat adults having short bowel syndrome (SBS). Also, it has been noticed that Gattex is quite expensive, with treatment costing over US$ 295,000 a year.

This global short bowel syndrome drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global short bowel syndrome drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In June 2021, VectivBio Holding AG announced that the FDA had granted orphan drug designation to Apraglutide. It is a next-generation, long-acting GLP-2 analog that is being developed for rare gastrointestinal diseases and used for the prevention of acute graft-versus-host disease (aGVHD).
• In April 2021, Hanmi Pharm. Co. Ltd. announced that the U.S. FDA had granted fast-track designation to its short-bowel syndrome therapy, LAPS GLP-2 Analog (HM15912). LAPS GLP-2 Analog is a new biopharmaceutical that has been developed for short-bowel syndrome with the company's platform technology, Labscovery. The disorder occurs in approximately 24.5 out of 100,000 newborns and majorly affects the growth of children and adolescents, with a survival rate under 50%.

Global Short Bowel Syndrome Drugs Market Scope

The global short bowel syndrome drugs market is segmented on the basis of drug class, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Glucagon-like Peptide
• Anti-Diarrheal
• Histamine Blockers
• Proton Pump Inhibitors
• Growth Hormone
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Short Bowel Syndrome Drugs Market Regional Analysis/Insights

The global short bowel syndrome drugs market is analyzed and market size insights and trends are provided by drug class, drug, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global short bowel syndrome drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for global short bowel syndrome drugs market throughout the forecasted period due to the high prevalence of short bowel syndrome and increase in research and development activity.

Asia-Pacific dominates the market due to the developing healthcare facilities, large number of generic manufacturers and rise in government initiatives and specialist communities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Short Bowel Syndrome Drugs Market Share Analysis

The global short bowel syndrome drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global short bowel syndrome drugs market.

Key players operating in the global short bowel syndrome drugs market include:

• Takeda Pharmaceutical Company Limited (Japan)
• Johnsons & Johnsons Services Inc (U.S.)
• Boehringer Ingelheim International GmbH (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Sanofi (France)
• GSK Plc. (U.K.)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• Amneal Pharmaceuticals LLC. (U.S.)
• Alvogen (U.S)
• Hikma Pharmaceuticals PLC (U.K.)